Many Advanced Cancer Patients Miss Out on Critical Genomic Testing

The recent data coming out of JAMA Network Open paints a sobering picture of the “precision gap” in oncology—a reality that hits home for many families navigating the complex healthcare corridors of Chicago, Illinois. While the medical community has seen the five-year survival rate for cancer climb to 70% as of 2026, the benefit of these breakthroughs isn’t reaching everyone equally. In a city where world-class research hubs exist just blocks away from underserved neighborhoods, the fact that roughly half of patients with certain metastatic cancers aren’t receiving the genomic sequencing necessary to access targeted therapies is a critical failure in delivery, not science.

The Disconnect Between Genomic Innovation and Patient Access

For patients dealing with advanced malignancies, genomic sequencing isn’t just a diagnostic curiosity; it is the roadmap for treatment. As highlighted in recent research, the arrival of targeted therapies—specifically poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors—means that the results of germline genetic testing (GT) now directly dictate clinical decisions. However, the transition from genetic counselor-led testing to oncologist-led testing has not solved the underlying accessibility crisis. The data reveals a stark disparity: patients with lower incomes, those relying on Medicare or Medicaid, and individuals from Black or Hispanic communities are significantly less likely to receive the sequencing that could potentially save their lives.

This disparity is particularly evident in the context of metastatic prostate cancer (mPCa). National guidelines strongly recommend next-generation sequencing (NGS) of tumors to identify actionable alterations. Yet, the struggle to implement these guidelines consistently across different socioeconomic strata remains a hurdle. In large-scale studies, such as those involving US veterans, it has been noted that non-Hispanic Black men often present with higher prostate-specific antigen levels at diagnosis and frequently reside in more deprived neighborhoods, factors that can intersect with the systemic barriers to receiving advanced genomic care.

The Impact of Delivery Models on Clinical Outcomes

The question for healthcare systems in hubs like Chicago is no longer “Do we have the technology?” but “How do we deliver it?” A national quality improvement study involving 1,964 patients with metastatic prostate cancer suggests a potential solution. The research found that embedding genetics clinicians directly within oncology clinics—rather than relying on the traditional model of external genetic consultation—was associated with greater efficiency and effectiveness in testing delivery. By removing the friction of separate appointments and fragmented referrals, the “embedded” model helps ensure that the right patients get the right tests at the right time.

Current guidelines emphasize the necessity of germline genetic testing for specific high-impact cancers, including metastatic ERBB2-negative breast cancer, metastatic prostate cancer, exocrine pancreatic cancer, and all stages of epithelial ovarian cancer. When these tests are bypassed, patients miss the opportunity to utilize precision medicine protocols that target the specific mutations driving their tumor’s growth.

Navigating the Genomic Landscape in Chicago

For those navigating the healthcare system in the Midwest, the presence of institutions like the Columbia University Irving Medical Center in the broader research network and the Department of Veterans Affairs (VA) National Precision Oncology Program underscores the importance of institutional support. The VA’s integrated health care system has attempted to address the lack of representation for non-Hispanic Black men in precision oncology cohorts, revealing that while alteration frequencies in key oncogenic pathways may differ by race, survival rates can be similar when access to NGS testing is equitable.

The goal is to move toward a system where a patient’s zip code or insurance provider doesn’t determine whether they receive a life-extending targeted therapy. The shift toward oncologist-led testing is a step in the right direction, but it must be paired with a conscious effort to bridge the gap for socioeconomically disadvantaged groups who have historically been left behind in the genomic revolution.

Local Resource Guide for Precision Oncology

Given my background in the biotech and health sectors, if you or a loved one are facing a metastatic cancer diagnosis in the Chicago area, it is imperative to be proactive about genomic testing. You should not wait for the provider to suggest it; instead, ask specifically about the guidelines for your specific cancer type. To ensure you are getting the highest standard of care, here are the three types of local professionals you should engage:

Precision Oncology Specialists

Gaze for oncologists who specialize in “molecular tumor boards” or targeted therapies. Ensure they have a documented history of utilizing next-generation sequencing (NGS) and can explain how the results will specifically alter your treatment plan, such as the use of PARP inhibitors.

Clinical Genetic Counselors

Seek counselors who are embedded within the oncology clinic or have a direct pipeline to your treating physician. They are essential for interpreting the complex data from germline testing and explaining the implications for both the patient and their biological family members.

Patient Navigators and Case Managers

Especially for those using Medicare or Medicaid, a dedicated patient navigator is crucial. Look for professionals who specialize in “access to care” and can assist overcome the administrative hurdles that often prevent low-income patients from receiving approved genomic sequencing.

Ready to find trusted professionals? Browse our complete directory of top-rated biotech,health,biotechnology,cancer,stat+ experts in the Chicago area today.